Abstract
The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Current Pharmaceutical Design
Title:Why do Psychotic Patients use Cannabis? Case Series
Volume: 18 Issue: 32
Author(s): Anna Kolliakou, Khalida Ismail and Zerrin Atakan
Affiliation:
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Abstract: The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Export Options
About this article
Cite this article as:
Kolliakou Anna, Ismail Khalida and Atakan Zerrin, Why do Psychotic Patients use Cannabis? Case Series, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884807
DOI https://dx.doi.org/10.2174/138161212802884807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nucleic Acid Aptamers Against Proteases
Current Medicinal Chemistry The Effect of Stress Management Program on Perceived Stress in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Current Diabetes Reviews Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Imaging Localised Hydrogen Peroxide Production in Living Systems
Current Chemical Biology BDNF-TrkB and proBDNF-p75NTR/Sortilin Signaling Pathways are Involved in Mitochondria-Mediated Neuronal Apoptosis in Dorsal Root Ganglia after Sciatic Nerve Transection
CNS & Neurological Disorders - Drug Targets In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ischemic Tolerance Induced by Normobaric Hyperoxia and Evaluation of Group I and II Metabotropic Glutamate Receptors
Current Neurovascular Research Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Editorial [ Hot Topic:Physical Activity, Exercise and Aging (Guest Editors: Yolanda Escalante and Jose M. Saavedra )]
Current Aging Science Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Microwave Assisted Synthetic Approach of New Pyridine based Benzothiazepines: Their Antibacterial and Antifungal Activities
Current Microwave Chemistry Anderson-Fabry Disease in Children
Current Pharmaceutical Design Guanine-Quadruplexes Studied by Fluorescence Techniques
Current Analytical Chemistry Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine Focusing on New Monoamine Oxidase Inhibitors: Differently Substituted Coumarins As An Interesting Scaffold
Current Topics in Medicinal Chemistry Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Drug Evolution: p-Aminobenzoic Acid as a Building Block
Current Medicinal Chemistry